ABL Bio Future Growth
Future criteria checks 5/6
ABL Bio is forecast to grow earnings and revenue by 54.8% and 25.5% per annum respectively. EPS is expected to grow by 106.2% per annum. Return on equity is forecast to be 9.1% in 3 years.
Key information
48.2%
Earnings growth rate
94.0%
EPS growth rate
| Biotechs earnings growth | 67.7% |
| Revenue growth rate | 24.7% |
| Future return on equity | 13.0% |
| Analyst coverage | Low |
| Last updated | 28 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 76,000 | 3,000 | 6,000 | 7,000 | 1 |
| 12/31/2025 | 82,000 | 11,000 | 5,000 | 5,000 | 1 |
| 12/31/2024 | 42,000 | -27,000 | -15,000 | -15,000 | 1 |
| 6/30/2024 | 32,955 | -40,003 | -73,541 | -64,894 | N/A |
| 3/31/2024 | 33,103 | -38,952 | -67,776 | -60,555 | N/A |
| 12/31/2023 | 65,547 | -2,647 | -34,206 | -28,362 | N/A |
| 9/30/2023 | 67,446 | -7,951 | 1,252 | 4,155 | N/A |
| 6/30/2023 | 97,254 | 23,608 | 5,534 | 8,498 | N/A |
| 3/31/2023 | 104,803 | 36,101 | 9,863 | 12,230 | N/A |
| 12/31/2022 | 67,301 | 3,209 | 69,746 | 72,132 | N/A |
| 9/30/2022 | 57,994 | 4,352 | 43,645 | 44,605 | N/A |
| 12/31/2021 | 5,332 | -43,558 | -41,871 | -40,605 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A298380 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: A298380 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A298380 is expected to become profitable in the next 3 years.
Revenue vs Market: A298380's revenue (25.5% per year) is forecast to grow faster than the KR market (9.7% per year).
High Growth Revenue: A298380's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A298380's Return on Equity is forecast to be low in 3 years time (9.1%).